- Home
- QGEN vs ASND Comparison
QGEN vs ASND Comparison
Compare QGEN & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- ASND
- Stock Information
- Founded
- QGEN 1986
- ASND 2006
- Country
- QGEN Netherlands
- ASND Denmark
- Employees
- QGEN N/A
- ASND 1017
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- QGEN Health Care
- ASND Health Care
- Exchange
- QGEN Nasdaq
- ASND Nasdaq
- Market Cap
- QGEN 9.9B
- ASND 9.1B
- IPO Year
- QGEN 1996
- ASND 2015
- Fundamental
- Price
- QGEN $40.04
- ASND $152.15
- Analyst Decision
- QGEN Buy
- ASND Strong Buy
- Analyst Count
- QGEN 8
- ASND 14
- Target Price
- QGEN $49.79
- ASND $201.79
- AVG Volume (30 Days)
- QGEN 1.1M
- ASND 408.5K
- Earning Date
- QGEN 04-28-2025
- ASND 05-01-2025
- Dividend Yield
- QGEN 3.31%
- ASND N/A
- EPS Growth
- QGEN N/A
- ASND N/A
- EPS
- QGEN 0.38
- ASND N/A
- Revenue
- QGEN $1,978,214,000.00
- ASND $376,478,932.00
- Revenue This Year
- QGEN $5.15
- ASND $61.43
- Revenue Next Year
- QGEN $6.49
- ASND $73.07
- P/E Ratio
- QGEN $103.78
- ASND N/A
- Revenue Growth
- QGEN 0.66
- ASND 36.34
- 52 Week Low
- QGEN $37.63
- ASND $111.09
- 52 Week High
- QGEN $47.93
- ASND $169.37
- Technical
- Relative Strength Index (RSI)
- QGEN 51.72
- ASND 47.92
- Support Level
- QGEN $39.31
- ASND $143.81
- Resistance Level
- QGEN $40.27
- ASND $158.45
- Average True Range (ATR)
- QGEN 0.55
- ASND 6.40
- MACD
- QGEN 0.16
- ASND -1.83
- Stochastic Oscillator
- QGEN 82.59
- ASND 32.61
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.